New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
Pre-specified pooled analysis from Phase III trials demonstrated reduction in CV death by 14% and reduction in death from any cause by 10% in patients with heart failure irrespective of ejection fraction First heart failure medication to demonstrate mortality benefit across the full ejection fraction range Results being presented at the European Society of Cardiology … [Read more…]
